24667-07-0Relevant academic research and scientific papers
A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors
Liang, Rui,Tomita, Daisuke,Sasaki, Yusuke,Ginn, John,Michino, Mayako,Huggins, David J.,Baxt, Leigh,Kargman, Stacia,Shahid, Maaz,Aso, Kazuyoshi,Duggan, Mark,Stamford, Andrew W.,DeStanchina, Elisa,Liverton, Nigel,Meinke, Peter T.,Foley, Michael A.,Phillips, Richard E.
supporting information, p. 377 - 387 (2022/02/25)
Aberrant gene-silencing through dysregulation of polycomb protein activity has emerged as an important oncogenic mechanism in cancer, implicating polycomb proteins as important therapeutic targets. Recently, an inhibitor targeting EZH2, the methyltransferase component of PRC2, received U.S. Food and Drug Administration approval following promising clinical responses in cancer patients. However, the current array of EZH2 inhibitors have poor brain penetrance, limiting their use in patients with central nervous system malignancies, a number of which have been shown to be sensitive to EZH2 inhibition. To address this need, we have identified a chemical strategy, based on computational modeling of pyridone-containing EZH2 inhibitor scaffolds, to minimize P-glycoprotein activity, and here we report the first brain-penetrant EZH2 inhibitor, TDI-6118 (compound 5). Additionally, in the course of our attempts to optimize this compound, we discovered TDI-11904 (compound 21), a novel, highly potent, and peripherally active EZH2 inhibitor based on a 7 member ring structure.
Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual acting α4β1 and α4β7 receptor antagonists
Tilley, Jefferson W.,Sidduri, Achyutharao,Lou, Jianping,Kaplan, Gerry,Tare, Nadine,Cavallo, Gary,Frank, Karl,Pamidimukkala, Anjula,Choi, Duk Soon,Gerber, Louise,Railkar, Aruna,Renzetti, Louis
, p. 1036 - 1040 (2013/03/13)
From a series of N-acyl 4-(3-pyridonyl)phenylalanine derivatives of 4, the trifluoromethyl derivative 28 was identified as a potent, dual acting alpha4 integrin antagonist with activity in primate models of allergic asthma. Investigation of a series of prodrug esters led to the discovery of the morpholinopropyl derivative 48 that demonstrated good intestinal fluid stability, solubility and permeability. Compound 48 gave high blood levels of 28 when dosed orally in cynomolgus monkeys. Surprisingly, hydrolysis of 48 was rapid in liver microsomes from the pharmacological species, mouse, rat and monkey, but slow in dog and human; in vivo studies also indicated there was prolonged exposure to unchanged prodrug in dogs.
